Slide 1: Corporate Presentation March 2024
£ipca A dose of life Ipca Laborate Corporate Presentation March 2024
Slide 2: About Us
About Us a Incorporation Total Income FY 2023- ve Employees 70+ | 7, 829.81 cs | >16,000 Wong ang : & years | facilities labs US$945 Mn
Slide 3: Our Values
Our Values a ( e Values « } Qualiti Safeti Integriti Digniti Responsibiliti Adhere to Ensure safety Comply with Value Facilitate good standards comes first ethics & standards people business practices
Slide 4: Five Years' Highlights (Standalone)
Five Years’ Highlights XN 6,277.75 %5,925.81 ($757.82) %5,491.22 ($738.69) bere (5737.38) &4,432.12 ($625.65) 3,570.05 2,983.09 <3282.39 ($430.96) 2,484.21 1983 ($409.17) 2,288.37 ($333.94) _ to ‘o——- —O -O —O— bl 2,717.19 2,508.13 2,643.42 Fei’ %2,143.75 (5365.26) (5336.80) ($329.52) . a 652.46 9"
Slide 5: Five Years' Highlights (Consolidated)
Five Years’ Highlights Consolidated f— 27,829.81 ($945.17) 8000 %6,369.94 7000 5,896.36 ($794.06) eee ($791.78) 6000 4,715.71 . 5000 (5665.68) 3,391.06 %4090.77 4000 Per eine ($422.72) ($493.82) 2,327.88 398.31 ‘ 3000 : %3,739.04 (5328.61) : (5451.35) 2000 2,818.61 2,978.88 -—O- i 2,387.83 Yea (5378
Slide 6: Manufacturing Facilities: Formulations
Slide 7: Manufacturing Facilities (Formulations)
Manufacturing Facilities (Formulations) Dehradun Kandla (2 facllities) (B-lactum) a New Delhi Jorethang (2 facilities) Ratlam B capital BD Corporate Office B® Formulations @ rap | SEZ - Pithampur Mumbai (Biotech -+ R&D) Piparia Pithampur Athal (Biotech) 0. aw
Slide 8: Manufacturing Facilities (Formulations) by site
Athal (Dadra & Nagar Haveli) Ratlam (Madhya Pradesh) Kandla (Gujarat) Silvassa (Dadra & Nagar Haveli) Dehradun (Uttarakhand) Indore (SEZ) (Madhya Pradesh) Sikkim Tarapur, Palghar (Maharashtra) Tablets & Capsules Tablets, Liquids, Dry Syrup, Injectables & Ointments Betalactum-Tablets, Capsules & Dry
Slide 9: Manufacturing Facilities: Active Pharmaceutical Ingredients
RRS Manufacturing Facilities larmaceutical Ingredients eae ‘
Slide 10: Manufacturing Facilities (APIs)
Manufacturing Facilities (APIs) Onyx Scientific (Sunderland, UK) (APIs + R&D) Dewas Nandesari Baroda | B capital BW Corporate Office @ as @ rap a rh Tye Ankleshwar Go Wardha § Aurangabad (2 Facilities) < Pisgah Labs Tarapur Vizag* Nellore* (North Carolina, USA) (APIs + R&D) Zs * Krebs Biochemical &
Slide 11: Manufacturing Facilities (APIs) Approvals
Manufacturing Facilities (APIs) [ Location | Inspections / Approvals by Agencies of ] e@ Ratlam (Madhya Pradesh) Australia, Brazil, Canada, EDQM, EU, India, Japan, Korea, Mexico, Russia, Slovenia, USA, WHO © Indore Madhya Pradesh) nig B,WHO @ Dewas (Madhya Pradesh) India © Ankleshwar(Gujart) = India
Slide 12: Revenue Break-up
Reven we Break- -up
Slide 13: Revenue Break-up (Standalone 2023-24)
Revenue Break-up (Standalone 2023-24) Total Total Revenue Exports Domestic 2023-24 2023-24 2023-24 2023-24 43% 46% 54% | e e e Formulations: APIs Formulations e e e e APIs Formulations ; Export Domestic : APIs B® Formulations @ APIs B® Domestic @ Exports B® Formulations @ APIs @ Formulations @ APIs
Slide 14: Revenue Break-up (Standalone)
Revenue Break-up (Standalone) 2023-24 2022-23 Crs | Domestic | Exports | Total | Domestic | Exports | Total Growth | © Branded Formulations 3097.16 526.70 3623.86 2760.71 504.79 3265.50 q pen isition/ : 1248.62 1248.62 : 1134.40 1134.40 © Total Formulations 3097.16 177532 4872.48 2760.71 1639.19 439
Slide 15: Financials FY 2022-23 & FY 2023-24
Slide 16: Standalone
Standalone FY 2023-24 FY 2022-23 Zs US$ Mn | (Rts US$ Mn | % Growth @ Total Income 6277.75 758 5925.81 — e EBIDT 1189.54 144 942.86 e EBIDT% 19.29% = 16.22% @ PBT* 955.52 115 750.49 e@ PBT% 15.5% = 12.91% @ PAT* 530.41 64 505.70 @ PAT% 8.60% = 8.70% # After forex gain of 21.84(Crs as against forex l
Slide 17: Financials Standalone Profitability
Financials Standalone CT Profitability | FY 2023-24 FY 2022-23 e PBIDT 19.29% @ point WB Pst WB PAT @ poiot WB Pst WB PAT
Slide 18: Business Characteristics
Business Characteristics Return on Capital Employed % (PBIT / Capital Employed) Return on Net Worth % (PAT / Net Worth) Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) Capital Employed Turnover Ratio (Total Income / Capital Employed) Asset Coverage Ratio (to term loan) (Net Fixed Assets
Slide 19: Financials Standalone
Financials Standalone FY 2023-24 FY 2022-23 @ Net Profit 4.9% 41.2%
Slide 20: Consolidated FY 2023-24 FY 2022-23
FY 2023-24 FY 2022-23 ZCrs US$ Mn | f ZCrs US$ Mn % Growth @ Total Income 7829.81 945 6369.94 e EBIDT 1288.21 156 958.28 e EBIDT% 16.72% - 15.35% @ PBT* 842.67 102 745.29 @ PBT% 10.94% - 11.94% e@ PAT* 547.35 66 471.32 e@ PAT% 7.10% - 7.55% # After forex gain of €32.95 Crs as against forex loss of $
Slide 21: Financials Consolidated Business Characteristics
Financials Consolidated Business Characteristics FY 2023-24 FY 2022-23 Return on Capital Employed % (PBIT / Capital Employed) 16.30% 15.21% Return on Net Worth % (PAT / Net Worth) 11.47% 10.71% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 2.12 2.92 Capital Employed Turnover Ratio (To
Slide 22: Financials Consolidated
Financials Consolidated FY 2023-24 FY 2022-23 @ Net Profit 9.2% 46.7%
Slide 23: Contribution of Therapeutic Groups
© Cardiovasculars& Anti-Diabetics © Anti-Malarials © ‘Neuro Psychiatry e 3% 3% © Dermatology e 6% 6% © Neutraceuticals e % 1% Ls os Financials Standalone Contribution of Therapeutic Groups a Weta Segment — 2023-24 Domestic 2022-23 Export 2023-24 2022-23 © Cardiovasculars & Anti-Diabetics © AntiMalar
Slide 24: Branded Formulations
Branded| Formulations
Slide 25: Branded Formulations Domestic
Branded Formulations a Domestic : 21 Market leaders in UTC ET OU Therapy Focused Over 4000 Rheumatoid Arthritis 16¢* (MAT Mar’24) Marketing Divisions Wholesalers & Anti-malarials Gy @ 24 Depots & Field Strength 5 brands among ‘1 CRF agent (PSR / BA)-6365 top 300 brands (Zerodol-SP, Zerodol-P, HCQS,
Slide 26: Branded Formulations Domestic Sales
Branded Formulations Domestic 3097.16 ($374.Mn) 2760.71 s000 2508.27 (5344 Mn) ($337 Mn) 2500 1981.67 2000 ($266 Mn) 1500 1000 500 —O— 2023-24 0 T T T 2020-21 L 2020-21 2021-22 2022-23 2023-24 ) aes Figures in Crores. Sales 6
Slide 27: Branded Formulations Domestic Future Growth Drivers
Branded Formulations Domestic Future Growth Clinical research as a tool to launch innovative combination Drivers formulations / NDDS. rail —® Strong brand building with focused promotion. -—® In-licensing / out-licensing to build business in the promoted therapy. Portfolio optimisation, strategies t
Slide 28: International
\ Intern ational
Slide 29: International Business
International Business a Registrations in 59 countries © Recognised _A Field-force to promote brands © Five Star Export gu in more than House 30 countries Products of the company 43% sales & Marketing offices in are now exported to over From exports By 12 countries 100 countries across the globe
Slide 30: International Business Sales
International Business (— >) 3000 %2717.19 %2643.42 %2707.70 ($365 Mn) 7 ($330 Mn) ($327 Mn) 2500 2000 1500 1000 500 —O— 2023-24 0 T T T 1 2020-21 L 2020-21 2021-22 2022-23 2023-24 ) O- mun Figures in Crores. Sales 30
Slide 31: Continent-wise Exports 2023-24
International Business a Continent-wise Exports 2023-24 (%Crs) Continent Formulations APIs | Total | % Contribution © Europe 468.73 315.26 783.99 29% © Africa 477.16 42.69 520.45 19% © Americas 184.88 255.49 440.37 16% @ Asia 134.18 267.10 401.28 15% e ds 206.76 45.89 252.65 9% © Australasia 303.01
Slide 32: International Formulations
Slide 33: International Formulations Sales
International Formulations %1639.19 1597.19 ($204 Mn) ($215 Mn) 1486.74 ($200 Mn) 1775.32 ($214 Mn) X 2020-21 2021-22 2022-23 2023-24 ~ wv —O— 2023-24 2020-21 2021-22 2022-23 Figures in Crores. Sales
Slide 34: International
Intern ational
Slide 35: International Branded Formulations
International Branded Formulations (— 526.70 > 530 504.79 ($64 Ma) _ ($63 Mn) 490 470 450 430 403.42 rer ($54Mn) 410 390 370 350 —O— 2023-24 330 T T T 1 2020-21 L 2020-21 2021-22 2022-23 2023-24 pe Figures in Crores. Sales 35
Slide 36: International Branded Formulations Future Growth Drivers
International Branded Formulations Future Growth _ Thrust on brand building in Pain, CVS, CNS, Anti-infective Drivers and Anti-malarial segments. ral '—® Geographical expansion in covered countries through additional field force. +—® Expansion in business lines - Institutions and Distributors. Intro
Slide 37: International Institution / Tender
@ eo ae tional NS nstitution / Tender so Ane SS 5
Slide 38: International Generics / Institution / Tender
International Generics / Institution / Tender >) Count Products Products Under 1400 %1248.62 ountry Registered Registration %1193.77 %1134.40 ($151 Mn) . . 1200 (5160 Mn) 1070.75 141 Mn) jae Kingdom 50 5 ($144 Mn) ure 1000 Australia / New Zealand @ é 800 South Africa 53 10 cou United States / 38 25
Slide 39: International Generics Future Growth Drivers
International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries. al Formulations registered to be backed by own API. Sale of generic dossiers with or without supply agreements. Contract manufacturing arrangements. Futur
Slide 40: International APIs
internat ational
Slide 41: International APIs Sales
International APIs ~ 1200 1120.00 (5151 Mn) %1021.39 %1004.23 ($137 Mn) ($125 Mn) £932.38 1000 (5113 Mn) 800 600 400 200 —O- 2023-24 0 T T T 2020-21 L 2020-21 2021-22 2022-23 2023-24 pe Figures in Crores. Sales
Slide 42: APIs - Drug Master Files
International APIs - Drug Master Files AA DME | Name of the API US-FDA Canada- who | /aPa% | Australia| EQDM 1 1 Alendronate Sodium () c - 7) - i) 2 2 Allopurinol (7) @ = = CEP @ 3 3 Amlodipine Besylate () : - - - @ 4 Amlodipine Besylate (AK4 Process) - - - = ° G@ 4 5 Amodiaquine HCI - - g@ - - - 5
Slide 43: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 11 12 12 13 13 14 14 15 16 15 17 16 18 19 17 20 18 21 19 22 Name of the API Benzarone Benzbromarone Bisoprolol Fumarate Carvedilol Cetrizine Hydrochloride (CZ Process) Cetrizine Hydrochloride (CZ5 / CZ6 Process) Chloroquine Phosphate Chlorthalidone (CT3 / CT7 Process) Chlo
Slide 44: APIs - Drug Master Files
International APIs - Drug Master Files AA DME | Name of the API usFpa | Canada yg | JPan justralia | EQDM 20 23 Dihydroartemesinin = ° g@ - - - n 24 Etodolac (ED6 Process) (7) = ° - - - 25 Etodolac(ED7 Process) () c - - - 7) 26 Famotidine - - - @ - @ 27 Famotidine (FM3 Process) > 2 - - - @ 23 28 ‘Fe
Slide 45: APIs - Drug Master Files
International ; APIs - Drug Master Files API-DMFs Filed as on Mar’24 (Based on DMFs Sr. No.) PI | DMF 7 Canada- Japan- st AG | Name of the API | US-FDA HPEB | WHO | PMDA | Australia | EQDM | 34 Hydrochlorothiazide (Process |) @ @ - @ CEP @ 28 35 Hydrochlorothiazide (Process Il) id > 2 2 - - 36 Hydro
Slide 46: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 35 45 36 46 37 47 48 38 49 50 39 51 40 52 4] 53 54 42 55 Name of the API Lumefantrine Meloxicam Mesalamine (MZ4 Process) Mesalazine Mesalazine (MZ4B Process) Metformin HCL (ML Process) Metformin HCL (ML2 Process) Methylphenidate HCI Metoclopramide Base Metoclopramide HCI M
Slide 47: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 43 56 57 44 x 45 59 46 60 47 61 48 62 49 63 50 64 51 65 52 66 Name of the API Metoprolol Succinate Metoprolol Tartrate Metoprolol Tartrate (03 / 05 Process) Midodrine Hydrochloride Nabumetone Nifedipine Olanzapine Ondansetron Base Ondansetron Hydrochloride Paroxetine HCI P
Slide 48: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 53 67 54 68 55 69 56 70 57 71 58 72 59 73 60 74 61 p 76 62 77 Name of the API Primaquine Phosphate Probenecid Proguanil Hydrochloride Promethazine Hydrochloride Propranolol HCI Pyrantel Embonate Pyrantel Pamoate Pyrimethamine Quetiapine Fumarate Quetiapine Fumarate (QT5 Pr
Slide 49: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 63 78 64 79 80 65 81 66 82 83 67 84 68 85 69 86 87 70 88 Name of the API Risendronate Sodium Hemi-Pentahydarate Risperidone Telmisartan Telmisartan (WT3A Process) Torsemide Tramadol Hydrochloride Tramadol Hydrochloride (YT3 Process) Trazodone Hydrochloride Triamterene Trim
Slide 50: APIs - Drug Master Files
API-DMFs Filed as on Mar’24 (Based on DMFs Sr. No.) International APIs - Drug Master Files ‘sto Jon, | Name of the API mn 89 n 9 B91 92 74 93 Trimethoprim (T4 Process) Valsartan (VA6 Process) Venlafexine Hydrochloride Warfarin Sodium Warfarin Sodium Clathrate Zaltoprofen | US-FDA | ¢ Japan- . | WHO
Slide 51: International APIs Future Growth Drivers
International APIs -—® Consolidate API business of Sartans across the globe. Future Growth Drivers ‘—® Long term strategic tie-ups with major South American / European formulators. Leverage the customer base of more than 1000 customers spread across 90 _A countries is well laid down platform to intr
Slide 52: Research & Development
AS Resear rh& Development
Slide 53: Research & Development Spending
Research & Development APls & Formulations ( >) Year | Crs | %to sales | 180 £156.49 3161.50 4.50% \ 2.64% 160 3146.46 271% 4.00% 2019-20 101.04 2.35% 126.67 140 545% 3.50% 2020-21 126.67 2.49% 120 Nida z00%3 2021-22 141.46 2.63% 100 2.50% 80 2.00% 2022-23 156.49 271% 60 1.50% 2023-24 161.50 2.64% 4
Slide 54: Research & Development APIs & Formulations
Research & Development APls & Formulations -—® Current scientist manpower of 550+. Research focus on developing APIs with non-infringing process and development of finished dosage forms. Development of NDDS for domestic and international market. 248 patent applications filed. Biotech / fermentation
Slide 55: Overview of Advanced Biotech Lab
Overview of Advanced Biotech Lab Biosimilar R&D and Bio-manufacturing -—® Established “state-of-the-art” R&D in 2015 for Mammalian based mAbs Capable of in-house development from “Clone to Commercialization” Single-use cGMP Bio-manufacturing Facility (DS+DP+QC) is being established and to be ready b
Slide 56: Strong Biosimilar Pipelines
Strong Biosimilar Pipelines a Molecules: Anti-cancer and Anti-inflammatory mAbs Stage of Development e 7 Monoclonal antibodies (mAbs) at various stages of the development UK/HC/IN/EU e Target markets India, UK,HC, EU, ROW hb ——— 2075-26 2006-27 followed by USA e Sought EMA and MHRA-UK Scientific Adv
Slide 57: Thank You